These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19414323)

  • 61. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2.
    Ziogas AC; Gavalas NG; Tsiatas M; Tsitsilonis O; Politi E; Terpos E; Rodolakis A; Vlahos G; Thomakos N; Haidopoulos D; Antsaklis A; Dimopoulos MA; Bamias A
    Int J Cancer; 2012 Feb; 130(4):857-64. PubMed ID: 21445972
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
    Osada T; Chong G; Tansik R; Hong T; Spector N; Kumar R; Hurwitz HI; Dev I; Nixon AB; Lyerly HK; Clay T; Morse MA
    Cancer Immunol Immunother; 2008 Aug; 57(8):1115-24. PubMed ID: 18193223
    [TBL] [Abstract][Full Text] [Related]  

  • 63. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.
    Zhang J; Silva T; Yarovinsky T; Manes TD; Tavakoli S; Nie L; Tellides G; Pober JS; Bender JR; Sadeghi MM
    Circ Res; 2010 Aug; 107(3):408-17. PubMed ID: 20538685
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.
    Prager GW; Lackner EM; Krauth MT; Unseld M; Poettler M; Laffer S; Cerny-Reiterer S; Lamm W; Kornek GV; Binder BR; Zielinski CC; Valent P
    Mol Oncol; 2010 Apr; 4(2):150-60. PubMed ID: 20106729
    [TBL] [Abstract][Full Text] [Related]  

  • 65. VEGF, which is elevated in the CSF of patients with hydrocephalus, causes ventriculomegaly and ependymal changes in rats.
    Shim JW; Sandlund J; Han CH; Hameed MQ; Connors S; Klagsbrun M; Madsen JR; Irwin N
    Exp Neurol; 2013 Sep; 247():703-9. PubMed ID: 23518418
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
    Kobold S; Hegewisch-Becker S; Oechsle K; Jordan K; Bokemeyer C; Atanackovic D
    Oncologist; 2009 Dec; 14(12):1242-51. PubMed ID: 20008305
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bevacizumab is active in malignant effusion.
    Pichelmayer O; Gruenberger B; Zielinski C; Raderer M
    Ann Oncol; 2006 Dec; 17(12):1853. PubMed ID: 16790519
    [No Abstract]   [Full Text] [Related]  

  • 68. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti.
    Ferrara N
    Int J Dev Biol; 2011; 55(4-5):383-8. PubMed ID: 21858763
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
    Wentink MQ; Broxterman HJ; Lam SW; Boven E; Walraven M; Griffioen AW; Pili R; van der Vliet HJ; de Gruijl TD; Verheul HM
    Br J Cancer; 2016 Oct; 115(8):940-948. PubMed ID: 27575850
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies.
    Soto-Ortiz L; Finley SD
    J Theor Biol; 2016 Apr; 394():197-211. PubMed ID: 26826488
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
    Fricke I; Mirza N; Dupont J; Lockhart C; Jackson A; Lee JH; Sosman JA; Gabrilovich DI
    Clin Cancer Res; 2007 Aug; 13(16):4840-8. PubMed ID: 17699863
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer.
    Park HS; Kwon WS; Park S; Jo E; Lim SJ; Lee CK; Lee JB; Jung M; Kim HS; Beom SH; Park JY; Kim TS; Chung HC; Rha SY
    J Immunother Cancer; 2019 Oct; 7(1):268. PubMed ID: 31639056
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
    Yang J; Yan J; Liu B
    Front Immunol; 2018; 9():978. PubMed ID: 29774034
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Platelet factor 4 regulates T cell effector functions in malignant pleural effusions.
    Mulet M; Zamora C; Porcel JM; Nieto JC; Pajares V; Muñoz-Fernandez AM; Calvo N; Esquerda A; Vidal S
    Cancer Lett; 2020 Oct; 491():78-86. PubMed ID: 32726613
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neuropilin 1: function and therapeutic potential in cancer.
    Chaudhary B; Khaled YS; Ammori BJ; Elkord E
    Cancer Immunol Immunother; 2014 Feb; 63(2):81-99. PubMed ID: 24263240
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pulling the trigger on the tumor's bodyguards: what puts Tregs out of action?
    Nolting J; Brossart P
    Immunotherapy; 2011 Jun; 3(6):693-5. PubMed ID: 21668301
    [No Abstract]   [Full Text] [Related]  

  • 77. Immunotherapy of tumor by targeting angiogenesis.
    Hou J; Tian L; Wei Y
    Sci China C Life Sci; 2004 Dec; 47(6):545-52. PubMed ID: 15620111
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulatory T cells: a possible promising approach to cancer recurrence induced by morphine.
    Gong L; Dong C; Ouyang W; Qin Q
    Med Hypotheses; 2013 Mar; 80(3):308-10. PubMed ID: 23313332
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TGF-
    Courau T; Nehar-Belaid D; Florez L; Levacher B; Vazquez T; Brimaud F; Bellier B; Klatzmann D
    JCI Insight; 2016 Jun; 1(9):e85974. PubMed ID: 27699271
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment.
    Hu C; Jiang X
    Biomed Pharmacother; 2017 Apr; 88():134-137. PubMed ID: 28103506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.